Bristol-Myers Squibb Company (BMY)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
BMY Insider Trading Activity
BMY Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $310,151 | 3 | 75 |
Sells | $38,931 | 1 | 25 |
Related Transactions
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 2 | $200,055 | 0 | $0 | $200,055 |
| BOERNER CHRISTOPHER S. | Chief Executive Officer | 1 | $110,096 | 0 | $0 | $110,096 |
| Holzer Phil M | SVP and Controller | 0 | $0 | 1 | $38,931 | $-38,931 |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Insider Activity of Bristol-Myers Squibb Company
Over the last 12 months, insiders at Bristol-Myers Squibb Company have bought $310,151 and sold $38,931 worth of Bristol-Myers Squibb Company stock.
On average, over the past 5 years, insiders at Bristol-Myers Squibb Company have bought $3.99M and sold $32.88M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) — $200,055. BOERNER CHRISTOPHER S. (Chief Executive Officer) — $110,096.
The last purchase of 2,000 shares for transaction amount of $110,096 was made by BOERNER CHRISTOPHER S. (Chief Executive Officer) on 2025‑02‑20.
List of Insider Buy and Sell Transactions, Bristol-Myers Squibb Company
| 2025-02-20 | BOERNER CHRISTOPHER S. | Chief Executive Officer | 2,000 <0.0001% | $55.05 | $110,096 | +8.16% | ||
| 2025-02-14 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 1,823.49 <0.0001% | $54.84 | $100,000 | +10.97% | ||
| 2024-11-04 | Sale | Holzer Phil M | SVP and Controller | 700 <0.0001% | $55.62 | $38,931 | +5.01% | |
| 2024-11-01 | Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 1,830 <0.0001% | $54.67 | $100,055 | +7.09% | ||
| 2023-12-05 | BOERNER CHRISTOPHER S. | Chief Executive Officer | 2,000 <0.0001% | $49.78 | $99,560 | +1.36% | ||
| 2023-11-28 | BOERNER CHRISTOPHER S. | Chief Executive Officer | 3,071 0.0002% | $48.86 | $150,049 | +3.86% | ||
| 2023-11-20 | Samuels Theodore R. II | director | 8,500 0.0004% | $49.81 | $423,385 | +3.54% | ||
| 2023-08-24 | Sale | Powell Ann | EVP, Chief Human Resources | 17,986 0.0009% | $61.25 | $1.1M | -16.48% | |
| 2023-08-03 | Sale | Plenge Robert M | EVP, Chief Research Officer | 732 <0.0001% | $61.14 | $44,754 | -16.03% | |
| 2023-05-03 | Sale | VESSEY RUPERT | EVP & President, Research | 50,385 0.0024% | $67.06 | $3.38M | -17.50% | |
| 2023-02-06 | Sale | Caforio Giovanni | Board Chair and CEO | 240,000 0.0115% | $74.65 | $17.92M | -15.58% | |
| 2023-02-06 | Sale | Powell Ann | EVP, Chief Human Resources | 11,183 0.0005% | $74.69 | $835,258 | -15.58% | |
| 2022-11-09 | Sale | Powell Ann | EVP, Chief Human Resources | 16,250 0.0008% | $80.45 | $1.31M | -15.73% | |
| 2022-11-07 | Sale | VESSEY RUPERT | EVP, Research & Early Dev. | 45,910 0.0022% | $78.88 | $3.62M | -14.63% | |
| 2022-09-20 | Sale | Caforio Giovanni | Board Chair and CEO | 25,000 0.0012% | $69.71 | $1.74M | +0.60% | |
| 2022-09-15 | Sale | Caforio Giovanni | Board Chair and CEO | 50,000 0.0023% | $71.84 | $3.59M | -2.21% | |
| 2022-09-14 | Sale | Powell Ann | EVP, Chief Human Resources | 25,000 0.0012% | $70.75 | $1.77M | -0.35% | |
| 2022-09-13 | Sale | Elkins David V | EVP, Chief Financial Officer | 133,951 0.0063% | $71.30 | $9.55M | -1.08% | |
| 2022-06-13 | Sale | Caforio Giovanni | Board Chair and CEO | 30,000 0.0014% | $74.04 | $2.22M | -0.89% | |
| 2022-06-06 | Sale | LEUNG SANDRA | EVP, General Counsel | 65,000 0.003% | $74.89 | $4.87M | -2.94% |
Insider Historical Profitability
| BOERNER CHRISTOPHER S. | Chief Executive Officer | 104626 0.0052% | $6.39M | 3 | 1 | +2.61% |
| Hirawat Samit | EVP,Chief Med.Offr.,Drug Dev. | 63932 0.0032% | $3.9M | 2 | 0 | |
| Holzer Phil M | SVP and Controller | 11760 0.0006% | $718,183.20 | 0 | 1 | |
| CELGENE CORP /DE/ | 10 percent owner | 7008510 0.3454% | $428.01M | 1 | 1 | +6.23% |
| ANDREOTTI LAMBERTO | director | 935571 0.0461% | $57.14M | 0 | 43 | |
| HOOPER ANTHONY C | SVP ComOps Pres USJap Int | 530806 0.0262% | $32.42M | 0 | 2 | |
| LEUNG SANDRA | EVP, General Counsel | 308627 0.0152% | $18.85M | 0 | 10 | |
| Cuss Francis M | EVP & CSO | 266033 0.0131% | $16.25M | 0 | 5 | |
| Caforio Giovanni | Board Chair and CEO | 236104 0.0116% | $14.42M | 0 | 19 | |
| Celentano John E | SVP HR Public Affairs & Philan | 213556 0.0105% | $13.04M | 0 | 5 | |
| Carlo de Notaristefani | Pres Tech Ops & Supp Fnctns | 197745 0.0097% | $12.08M | 0 | 4 | |
| Bancroft Charles A | EVP & Chief Financial Officer | 184694 0.0091% | $11.28M | 0 | 5 | |
| Cazala Beatrice J | EVP Commercial Operations | 173375 0.0085% | $10.59M | 0 | 5 | |
| SIGAL ELLIOT | EVP, CSO & President R&D | 148221 0.0073% | $9.05M | 1 | 10 | +21.6% |
| CORNELIUS JAMES M | director | 119464 0.0059% | $7.3M | 2 | 116 | +5.54% |
| Elkins David V | EVP, Chief Financial Officer | 100460 0.005% | $6.14M | 0 | 2 | |
| von Autenried Paul | EVP, Chief Information Officer | 63536 0.0031% | $3.88M | 0 | 10 | |
| Elicker John E | EVP, Investor Relations | 58666 0.0029% | $3.58M | 0 | 9 | |
| ZABOR DAVID L | VP Strat Bus Initiatives | 54670 0.0027% | $3.34M | 0 | 1 | |
| DANIELS BRIAN | SVP Global Dev & Med Affairs | 53549 0.0026% | $3.27M | 0 | 7 | |
| VESSEY RUPERT | EVP & President, Research | 47751 0.0024% | $2.92M | 0 | 9 | |
| Caldarella Joseph C | SVP & Controller | 46297 0.0023% | $2.83M | 0 | 15 | |
| SKULE JOHN L III | SVP, Corp & Envirn Affairs | 39857 0.002% | $2.43M | 0 | 2 | |
| Samuels Theodore R. II | director | 35500 0.0017% | $2.17M | 5 | 0 | +7.3% |
| Schmukler Louis S | EVP,Pres.,Glob.Prod. & Supply | 31956 0.0016% | $1.95M | 0 | 11 | |
| Moed Samuel J | SVP, Strat Plan & Analysis | 31015 0.0015% | $1.89M | 0 | 6 | |
| Powell Ann | EVP, Chief Human Resources | 27868 0.0014% | $1.7M | 0 | 5 | |
| Nielsen Anne | Chief Compliance & Ethics Off | 28126 0.0014% | $1.72M | 0 | 1 | |
| Zito Robert T | SVP & Chief Comm Officer | 24016 0.0012% | $1.47M | 0 | 1 | |
| MCBRIDE ANTHONY A | SVP Human Resources | 24637 0.0012% | $1.5M | 0 | 1 | |
| Huet Jean-Marc | EVP & CFO | 25000 0.0012% | $1.53M | 1 | 0 | +21.6% |
| Paliwal Dinesh C | director | 22109 0.0011% | $1.35M | 2 | 0 | +7.67% |
| Santiago Karen Murphy | SVP & Controller | 16704 0.0008% | $1.02M | 0 | 2 | |
| Dubow Adam | SVP,ChiefCompliance&EthicsOff. | 13777 0.0007% | $841,370.67 | 0 | 5 | |
| BERTOLINI ROBERT J | director | 11397 0.0006% | $696,014.79 | 1 | 0 | +34.48% |
| Lynch Thomas J. Jr. | EVP & Chief Scientific Officer | 9251 0.0005% | $564,956.37 | 0 | 1 | |
| BONNEY MICHAEL W | director | 7189 0.0004% | $439,032.23 | 1 | 0 | +5.24% |
| Eid Joseph | SVP,Head Glob. Medical Affairs | 8069 0.0004% | $492,773.83 | 0 | 2 | |
| Plenge Robert M | EVP, Chief Research Officer | 6584 0.0003% | $402,084.88 | 0 | 1 | |
| FUTTER ELLEN V | director | 4894 0.0002% | $298,876.58 | 0 | 1 | |
| GROBSTEIN MICHAEL | director | 3383 0.0002% | $206,599.81 | 2 | 1 | +5.43% |
| LACY ALAN J | director | 2305 0.0001% | $140,766.35 | 0 | 1 | |
| CAMPBELL LEWIS B | director | 0 0% | $0 | 0 | 5 | |
| GLIMCHER LAURIE H M.D. | director | 0 0% | $0 | 0 | 2 |
Historical Insider Profitability vs. Competitors
$364,217,072 | 28 | 9.11% | $20.62B | |
$6,077,160 | 24 | 3.21% | $394.32B | |
$1,922,773,492 | 23 | 18.03% | $794.01B | |
$28,542,809 | 19 | 26.40% | $370.74B | |
Bristol-Myers Squibb Company (BMY) | $23,029,445 | 18 | 9.34% | $123.93B |
$1,995,978 | 16 | -0.53% | $148.94B | |
$17,024,470 | 16 | 4.30% | $235.2B | |
$3,170,734 | 10 | 3.98% | $169.78B | |
$3,933,798 | 8 | 12.50% | $133.35B | |
$252,679 | 2 | 0.47% | $3.97B |
BMY Institutional Investors: Active Positions
| Increased Positions | 1,278 | +53.86% | 154M | +9.92% |
| Decreased Positions | 1,051 | -44.29% | 105M | -6.79% |
| New Positions | 338 | New | 24M | New |
| Sold Out Positions | 128 | Sold Out | 8M | Sold Out |
| Total Postitions | 2,600 | +9.57% | 2B | +3.13% |
BMY Ownership Change vs Market
Institutional Investor Ownership
| Vanguard Group Inc | $11.21M | 9.36% | 189.94M | +1M | +0.73% | 2024-12-31 |
| Blackrock, Inc. | $9.3M | 7.77% | 157.61M | -2M | -1.28% | 2024-12-31 |
| Jpmorgan Chase & Co | $5.67M | 4.73% | 96.02M | +18M | +23.22% | 2024-12-31 |
| State Street Corp | $5.61M | 4.69% | 95.14M | +2M | +2.42% | 2024-12-31 |
| Charles Schwab Investment Management Inc | $3.56M | 2.97% | 60.3M | -729,928 | -1.2% | 2024-12-31 |
| Capital International Investors | $2.71M | 2.26% | 45.87M | +3M | +7.55% | 2024-12-31 |
| Geode Capital Management, Llc | $2.62M | 2.19% | 44.39M | +1M | +2.75% | 2024-12-31 |
| Norges Bank | $2.08M | 1.73% | 35.18M | +3M | +7.92% | 2024-12-31 |
| Ameriprise Financial Inc | $1.89M | 1.58% | 32.08M | +12M | +59.86% | 2024-12-31 |
| Fmr Llc | $1.84M | 1.53% | 31.11M | -14M | -30.77% | 2024-12-31 |